We investigate the utilization pattern and self-reported compliance with topical 0.05% cyclosporine emulsion in patients with dry eye. In 136 patients with dry eye using 0.05% cyclosporine emulsion, the level of compliance, the symptoms before and after use, the length of time taken before symptoms improved and adverse effects when use were evaluated. Eighty two percent of 136 patients used at least 1 box of 0.05% cyclosporine emulsion. One hundred and sixty patients were divided into three groups. Patients whose compliance level was higher than 50% were assigned to Group I; those with a compliance level between 25 to 50% belonged to Group II and those whose compliance was less than 25% were in Group III. The symptom score of all subjects decreased from 2.96 before cyclosporine use to 1.72 (p=0.011) after cyclosporine use. Patients in Group I experienced an improvement in their symptoms earlier (4.3 months) compared to those in Group II (6.5 months, p=0.030) and Group III (9.6 months, p=0.010). Adverse effects were experienced in 60% of patients, the most common being a sensation of pain (20%) and burning (20%). Patients who had the highest level of compliance noticed an improvement in their symptoms earliest. Patients need to be given detailed explanations about the adverse events of 0.05% cyclosporine emulsion.

